Stoney!!!! I just went thru the thread for the last week. You had 7 losers! Big ones too. What's worse that the readers depend on... you were 100% wrong on the market direction. I wasn't much better with individual stocks except for SNAP and LAND (SNAP we both liked).... but I am batting 1000+ on market direction.... ....YOU'RE WELCOME LIZARD KING.
First off If I was wrong on direction-- How did I make us 7 grand? I have you over 100 S&P points which you watched up and called a perfect trading bottom on Thurs. Did you? No. 2nd of all I don't have seven losers I only Bought two stocks. BYCL & S. So there. You cannot make this shit up--
LIZARD KING GAVE YOU 100 S&P POINTS FOR THE 4TH CONSECUTIVE 100 POINT S&P MOVE ALL SIC CALLED CORRECTLY. Anybody else doing that? No. S&P 500 (^GSPC) SNP - SNP Real Time Price. Currency in USD Add to watchlist 3,919.84-35.16(-0.89%)<--------------------- As of 10:24AM EDT. #6384 Thursday at 3:27 PM Report Reply Share S&P 500 (^GSPC) SNP - SNP Real Time Price. 4,001.36+34.51(+0.87%)<---------- As of 10:24AM EDT. Better Get Reading Van you missing all the action. $$$$$$$$$$$$$$$$$$$ GBA #1 FOR A REASON $$$$$$$$$$$$$$$$$$$
Do we have a bit of a silver run- WPM Wheaton Precious Metals Corp. 31.15 +1.39 +4.67% EXK Endeavour Silver Corp. 2.8200 +0.0900 +3.30% GATO Gatos Silver, Inc. 2.8100 +0.0300 +1.08%
Top 5 gainers in energy and natural resources during the past 5 days: (AREC)+14.2%, (NETI)+12.2%, (BORR)+11.2%, (LEU)+9.7%, (PLM)+8.3%.
Kohl's jumps on report of $2B offer for real estate Sep. 02, 2022 10:40 AM ETKohl's Corporation (KSS)FRG Kohl's (NYSE:KSS)rose 7.7%on a report that private equity firm Oak Street Real Estate made an offer to buy as much as $2 billion of property from the department store chain. Oak Street offered between $1.5 billion and $2 billionto buy real estate and the two sides have met in the last couple days to talk about a possible transaction, according to aReuters report.No certainty that a deal will be reached.
Very Int from BofA- All the drivers of the 21st century valuation model are reversing, according to BofA Securities. The "S&P500 (SP500) (NYSEARCA:SPY) generated $220 of EPS past 12 months," strategist Michael Hartnett in the weekly FlowShow note Friday. Applying "a 20th century PE of roughly 15x gets you to an S&P500 index of 3300 (our view), applying a 21st century PE of 20x gets you to an S&P500 of 4400." But the drivers of the 20x PE - QE, fiscal austerity, free movement of trade and people, people and capital and geopolitical peace - are ebbing away, Hartnett said. The new regime of higher inflation means that the "secular view remains cash, commodities, volatility to outperform bonds & stocks" and "inflation in things we don't have enough of: energy, workers, places to rent, food, raw materials, good infrastructure, military equipment." Deflation will be in government debt, office space, mobile phones and streaming content, he added. Investors should wait until the S&P 3,600/3,700 area to nibble on equities with new highs in yields (TBT) (TLT) (SHY) and new lows in stocks (SPY) (QQQ) (IWM) arrive, Hartnett said. Looking to the broader economy, Hartnett said that the housing sector is the only part of the economy showing "sinister trends." Nominal growth is still being boosted by "inflation, fiscal stimulus, past era of wealth accumulation, new era of 'economic cancel culture' (economic pain elicits immediate public sector bailout)." War is always inflationary, he added.
Signify Health jumps on report CVS in talks to acquire for about $8 billion --MacroGenics' total revenue consisting primarily of revenue from collaborative agreements was $26 million for the quarter ended June 30, --Revenue for the quarter ended June 30, 2022 included MARGENZA net sales of $4.7 million compared to $3.2 million for the quarter ended June 30, 2021. As a reminder, MARGENZA was launched in the U.S. in March 2021 in coordination with our commercial partner, EVERSANA. --Our research and development expenses were $51.7 million for the quarter ended June 30, 2022 compared to $55.8 million for the quarter ended --Our cash, cash equivalents, and marketable securities balance as of June 30, 2022 was $133.7 million compared to $243.6 million as of December 31 2021.
Finally, in terms of our cash runway, we anticipate that our cash, cash equivalents, and marketable securities balance as of June 30, 2022 was $34.5 million in payments subsequently received from collaboration partners, projected and anticipated payments from partners, product revenues, plus anticipated savings from our corporate restructuring plan announced today which Scott will walk through momentarily should extend our cash runway into 2024. This updated cash runway guidance now reflects anticipated expenditures related to the planned Phase 2 MGC018 Phase 2/3 study in metastatic castration resistant prostate cancer. Sept 2021